PREVENTIVE ACTION OF ORLISTAT ON CARDIOVASCULAR RISKS IN YOUNG OBESITY PATIENTS
Aim. To study the dynamics of cardiovascular risk factors in younger patients with obesity at the background of orlistat reception (Xenalten® 120 mg). Material and methods. The prospective study is done of the orlistat usage among 189 women and men at the age 18-44 y.o. during 3 years, of those 107...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2015-08-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/245 |
| Summary: | Aim. To study the dynamics of cardiovascular risk factors in younger patients with obesity at the background of orlistat reception (Xenalten® 120 mg). Material and methods. The prospective study is done of the orlistat usage among 189 women and men at the age 18-44 y.o. during 3 years, of those 107 women and 82 men. Comparison group (n=65) consisted of healthy men and women. The main group (n=189) took orlistat 120 mg t.i.d. with a meal, together with hypocaloric diet and aerobic activities. All studied patients were selected into 3 groups according to the duration of the drug intake (6, 12, 24 months) and obesity grade (I, II, III). During the study anthropometric parameters were assessed as the parameters of lipid, carbohydrate metabolism, blood pressure, vessel wall condition: intima-media thickness of systolodiastolic relation, time of acceleration and index of acceleration. All comparisons were double-compared with significance threshold as <0,01.Results. The most significant results were obtained in II and III degree of obesity patients taking the drug for 12 or 24 months — the decrease of waist circumference by 25,9% and 26,4%, lipid and glycemic profiles normalization, decrease of mean systolic arterial pressure and normalization of nocturnal blood pressure. The decrease of bodyweight by 23,8±0,31 kg among the main group and by 5,2±0,02 kg among the comparison group, and improvement of lipid profile with the treatment decreased the risk of ischemic heart disease. In patients after 6 months of orlistat intake the relation of triglycerides to high density cholesterol lipids decreased by 40,0%, and taking for 12 months — by 73,1%, for 24 months — 74,1%. Orlistat was well tolerated. Most adverse events in the main group were mild, and can be simply regarded as expected side effects. Conclusion. The clinically significant effectiveness of orlistat capsule 120 mg is found, for the complex treatment of obesity and for the decrease of cardiovascular risk factors as dyslipidemia, arterial hypertension, insulin resistance. The usage of the drug helps to retain patients ability and adherence to obesity treatment. |
|---|---|
| ISSN: | 1728-8800 2619-0125 |